A double‐blind, parallel, multicenter comparison of L‐acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys

Diagnostic and Statistical Manual of Mental Disorders

(2012) · Springer eBooks · doi:10.1007/springerreference_121117 · Cited by 20,769 · see citing works

A simple salting out procedure for extracting DNA from human nucleated cells

Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.3.1215 · Cited by 20,341 · see citing works

Diagnostic and Statistical Manual of Mental Disorders, 5th Edition

(2013) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890425596.893619 · Cited by 4,390 · see citing works

Vineland Adaptive Behavior Scales

Sparrow, S. S. (2010) · Springer eBooks · doi:10.1007/978-0-387-79948-3_1602 · Cited by 1,974 · see citing works

Carnitine—metabolism and functions

Bremer, J. (1983) · Physiological Reviews · doi:10.1152/physrev.1983.63.4.1420 · Cited by 1,666 · see citing works

Conners' rating scales-revised : technical manual

Conners, C. K. (1997) · Medical Entomology and Zoology · Cited by 1,014 · see citing works

Biostatistics: A Foundation for Analysis in the Health Sciences.

Daniel, W. W. (1988) · Biometrics · doi:10.2307/2531929 · Cited by 621 · see citing works

Autosomal XX sex reversal caused by duplication ofSOX9

Huang, B., Wang, S., Ning, Y., Lamb, A. N., & Bartley, J. A. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19991203)87:4 · Cited by 424 · see citing works

Autism Spectrum Phenotype in Males and Females with Fragile X Full Mutation and Premutation

Clifford, S. M., Dissanayake, C., Bui, M., Huggins, R., Taylor, A. K., & Loesch, D. Z. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0205-z · Cited by 380 · see citing works

Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome

Restivo, L., Ferrari, F., Passino, E., Sgobio, C., Bock, J., Oostra, B. A., Bagni, C., & Ammassari-Teule, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504984102 · Cited by 299 · see citing works

Fragile X Syndrome

Hagerman, R. J. (2002) · doi:10.56021/9780801868436 · Cited by 299 · see citing works

Specification of the Neurobehavioral Phenotype in Males with Fragile X Syndrome

Baumgardner, T. L., Reiss, A. L., Freund, L. S., & Abrams, M. T. (1995) · PEDIATRICS · doi:10.1542/peds.95.5.744 · Cited by 245 · see citing works

In Vitro Reactivation of the FMR1 Gene Involved in Fragile X Syndrome

Chiurazzi, P., Pomponi, M. G., Willemsen, R., Oostra, B. A., & Neri, G. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.1.109 · Cited by 198 · see citing works

Relative Carnitine Deficiency in Autism

Filipek, P. A., Juranek, J. J., Nguyen, M. T., Cummings, C., & Gargus, J. J. (2004) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-004-5283-1 · Cited by 197 · see citing works

Abuse and toxicity of methylphenidate

Klein‐Schwartz, W. (2002) · Current Opinion in Pediatrics · doi:10.1097/00008480-200204000-00013 · Cited by 168 · see citing works

A controlled trial of stimulant medication in children with the fragile X syndrome

Hagerman, R. J., Murphy, M. A., & Wittenberger, M. D. (1988) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320300138 · Cited by 158 · see citing works

Utilization of Citrate, Acetylcarnitine, Acetate, Pyruvate and Glucose for the Synthesis of Acetylcholine in Rat Brain Slices

Doležal, V., & Tuček, S. (1981) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1981.tb00569.x · Cited by 141 · see citing works

The psychological profile of the fragile X syndrome

Fryns, J. P., Jacobs, J., Kleczkowska, A., & BERGHE, H. V. D. (1984) · Clinical Genetics · doi:10.1111/j.1399-0004.1984.tb00474.x · Cited by 121 · see citing works

Adverse Side Effects of Methylphenidate among Mentally Retarded Children with ADHD

Handen, B. L., Feldman, H. M., GOSLING, A., Breaux, A. M., & McAuliffe, S. (1991) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199103000-00012 · Cited by 120 · see citing works

Fragile X syndrome

Hagerman, R. J., & Hagerman, P. J. (2002) · Cambridge University Press eBooks · doi:10.1017/cbo9780511543876.009 · Cited by 107 · see citing works

Fenfluramine and Methylphenidate in Children with Mental Retardation and ADHD: Clinical and Side Effects

Aman, M. G., KERN, R. A., McGhee, D. E., & Arnold, L. E. (1993) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199307000-00022 · Cited by 107 · see citing works

NMR Spectroscopic Studies of 13 C Acetate and 13 C Glucose Metabolism in Neocortical Astrocytes: Evidence for Mitochondrial Heterogeneity

Sonnewald, U., Westergaard, N., Hassel, B., Müller, T., Unsgård, G., Fonnum, F., Hertz, L., Schousboe, A., & Petersen, S. B. (1994) · Developmental Neuroscience · doi:10.1159/000111355 · Cited by 104 · see citing works

Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments

Tabolacci, E., Pietrobono, R., Moscato, U., Oostra, B. A., Chiurazzi, P., & Neri, G. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201393 · Cited by 92 · see citing works

Efficacy of Methylphenidate Among Mentally Retarded Children With Attention Deficit Hyperactivity Disorder

Handen, B. L., Breaux, A. M., Gosling, A., Ploof, D. L., & Feldman, H. M. (1990) · PEDIATRICS · doi:10.1542/peds.86.6.922 · Cited by 91 · see citing works

Acetyl-l-carnitine enhances acetylcholine release in the striatum and hippocampus of awake freely moving rats

Impérato, A., Ramacci, M. T., & Angelucci, L. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90826-4 · Cited by 87 · see citing works

A majority of fragile X males with methylated, full mutation alleles have significant levels of FMR1messenger RNA

Tassone, F., Hagerman, R. J., Taylor, A. K., & Hagerman, P. J. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.7.453 · Cited by 78 · see citing works

Noninvasive Test for Fragile X Syndrome, Using Hair Root Analysis

Willemsen, R., Anar, B., de Diego‐Otero, Y., Vries, B. B. A. D., Hilhorst‐Hofstee, Y., Smits, A. P. T., van Looveren, E., Willems, P. J., GALJAARD, H., & Oostra, B. A. (1999) · The American Journal of Human Genetics · doi:10.1086/302462 · Cited by 72 · see citing works

Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder

van Oudheusden, L. J., & Scholte, H. R. (2002) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1054/plef.2002.0378 · Cited by 70 · see citing works

Long-Term Follow-Up of Children with Mental Retardation/Borderline Intellectual Functioning and ADHD

Handen, B., Janosky, J., & McAuliffe, S. (1997) · Journal of Abnormal Child Psychology · doi:10.1023/a:1025760302598 · Cited by 62 · see citing works

Levels of carnitines in brain and other tissues of rats of different ages: Effect of acetyl-L-carnitine administration

Maccari, F., Arseni, A., Chiodi, P., Ramacci, M. T., & Angelucci, L. (1990) · Experimental Gerontology · doi:10.1016/0531-5565(90)90043-2 · Cited by 62 · see citing works

Studies on the metabolic pathway of the acetyl group for acetylcholine synthesis

Gibson, G. E., & Shimada, M. (1980) · Biochemical Pharmacology · doi:10.1016/0006-2952(80)90325-1 · Cited by 61 · see citing works

High Uptake of [2-11C]Acetyl-l-Carnitine into the Brain: A Pet Study

Kuratsune, H., Watanabe, Y., Yamaguti, K., Jacobsson, G., Takahashi, M., Machii, T., Onoe, H., Onoe, K., Matsumura, K., Valind, S., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.5919 · Cited by 49 · see citing works

Action of L-Acetylcarnitine on Different Cerebral Mitochondrial Populations from Cerebral Cortex

Gorini, A., D’Angelo, A., & Villa, R. F. (1998) · Neurochemical Research · doi:10.1023/a:1020907400905 · Cited by 34 · see citing works

Type V collagen regulates the assembly of collagen fibrils in cultures of bovine vascular smooth muscle cells

Kypreos, K. E., Birk, D. E., Trinkaus‐Randall, V., Hartmann, D. J., & Sonenshein, G. E. (2000) · Journal of Cellular Biochemistry · doi:10.1002/1097-4644(20010101)80:1 · Cited by 34 · see citing works

Effects of Acetyl-L-carnitine on Cardiac Dysautonomia in Rett Syndrome: Prevention of Sudden Death?

Guideri, F., Acampa, M., Hayek, J., & Zappella, M. (2005) · Pediatric Cardiology · doi:10.1007/s00246-005-0784-z · Cited by 31 · see citing works

Effect of acetyl-l-carnitine on hyperactivity and spatial memory deficits of rats exposed to neonatal anoxia

Dell’Anna, E., Iuvone, L., Calzolari, S., & Geloso, M. C. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)13411-5 · Cited by 30 · see citing works

Energy Metabolism of Synaptosomal Subpopulations from Different Neuronal Systems of Rat Hippocampus: Effect of L-Acetylcarnitine Administration In Vivo

Gorini, A., D’Angelo, A., & Villa, R. F. (1999) · Neurochemical Research · doi:10.1023/a:1021008306414 · Cited by 27 · see citing works

Butyrate and acetyl‐carnitine inhibit the cytogenetic expression of the fragile X in vitro

Pomponi, M. G., & Neri, G. (1994) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320510428 · Cited by 26 · see citing works

The effect of acetyl-l-carnitine administration on persons with Down syndrome

Pueschel, S. M. (2006) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2004.07.009 · Cited by 24 · see citing works

Analysis of mutations at the fragile X locus using the DNA probe Ox1.9

Snow, K., Doud, L. K., Hagerman, R. J., Hull, C. E., Hirst, M. C., Davies, K. E., & Thibodeau, S. (1992) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320430139 · Cited by 24 · see citing works

Effect of acetyl-l-carnitine on extracellular amino acid levels in vivo in rat brain regions

Tóth, E., Hársing, L. G., Sershen, H. W., Ramacci, M. T., & Lajtha, Á. (1993) · Neurochemical Research · doi:10.1007/bf00966933 · Cited by 24 · see citing works

Modulation of methylation in the FMR1 promoter region after long term treatment with L-carnitine and acetyl-L-carnitine

Pascale, E., Battiloro, E., Reale, G. C., Pietrobono, R., Pomponi, M. G., Chiurazzi, P., Nicolai, R., Calvani, M., Neri, G., & D’Ambrosio, E. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.6.e76 · Cited by 18 · see citing works

Advances in the Treatment of Fragile X Syndrome

Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596 · see citing works

Therapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder

Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404 · see citing works

Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics

Bagni, C., Tassone, F., Neri, G., & Hagerman, R. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63141 · Cited by 321 · see citing works

Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model

Naviaux, J. C., Wang, L., Li, K., Bright, A., Alaynick, W. A., Williams, K. R., Powell, S. B., & Naviaux, R. K. (2015) · Molecular Autism · doi:10.1186/2040-2392-6-1 · Cited by 285 · see citing works

Updated report on tools to measure outcomes of clinical trials in fragile X syndrome

Budimirovic, D. B., Berry‐Kravis, E., Erickson, C. A., Hall, S. S., Hessl, D. R., Reiss, A. L., King, M. K., Abbeduto, L., & Kaufmann, W. E. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9193-x · Cited by 157 · see citing works

Outcome Measures for Clinical Trials in Fragile X Syndrome

Berry‐Kravis, E., Hessl, D. R., Abbeduto, L., Reiss, A. L., Beckel-Mitchener, A. C., & Urv, T. K. (2013) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e31829d1f20 · Cited by 154 · see citing works

Fragile X: A Family of Disorders

Chonchaiya, W., Schneider, A., & Hagerman, R. J. (2009) · Advances in Pediatrics · doi:10.1016/j.yapd.2009.08.008 · Cited by 152 · see citing works

Potential serum biomarkers from a metabolomics study of autism

Wang, H., Liang, S., Wang, M., Gao, J., Sun, C., Wang, J., Xia, W. T., Wu, S., Sumner, S., Zhang, F., et al. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140009 · Cited by 121 · see citing works

Carnitine derivatives

Malaguarnera, M. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283505a3b · Cited by 105 · see citing works

Fragile X Syndrome and Targeted Treatment Trials

Hagerman, R. J., Lauterborn, J. C., Au, J., & Berry‐Kravis, E. (2011) · Results and problems in cell differentiation · doi:10.1007/978-3-642-21649-7_17 · Cited by 104 · see citing works

Fragile X syndrome: From protein function to therapy

Bagni, C., & Oostra, B. A. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36241 · Cited by 104 · see citing works

Diet in the treatment of ADHD in children—A systematic review of the literature

Rytter, M. J. H., Andersen, L. B. B., Houmann, T., Bilenberg, N., Hvolby, A., Mølgaard, C., Michaelsen, K. F., & Lauritzen, L. (2014) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2014.921933 · Cited by 103 · see citing works

Acetyl-l-Carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects

Martinotti, G., Andreoli, S., Reina, D., Nicola, M. D., Ortolani, I., Tedeschi, D., Fanella, F., Pozzi, G., Iannoni, E., D'Iddio, S., et al. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.01.013 · Cited by 98 · see citing works

Nutrient supplementation approaches in the treatment of ADHD

Rucklidge, J. J., Johnstone, J. M., & Kaplan, B. J. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.7 · Cited by 97 · see citing works

Acetyl-l-carnitine provides effective in vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain

Alves, E. A., BINIENDA, Z. K., Carvalho, F. D., Alves, C. J., Fernandes, E. G. R., Bastos, M. D. L., Tavares, M. A., & Summavielle, T. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.10.041 · Cited by 91 · see citing works

The Psychiatric Presentation of Fragile X: Evolution of the Diagnosis and Treatment of the Psychiatric Comorbidities of Fragile X Syndrome

Tranfaglia, M. R. (2011) · Developmental Neuroscience · doi:10.1159/000329421 · Cited by 89 · see citing works

Complementary medicines (herbal and nutritional products) in the treatment of attention deficit hyperactivity disorder (adhd): A systematic review of the evidence

Sarris, J., Kean, J., Schweitzer, I., & Lake, J. (2011) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2011.06.007 · Cited by 86 · see citing works

Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach usPreprint

Santos, A. R., Kanellopoulos, A. K., & Bagni, C. (2014) · Learning & Memory · doi:10.1101/lm.035956.114 · Cited by 86 · see citing works

Epileptiform activity and cognitive deficits in SNAP-25(+/-) mice are normalized by antiepileptic drugs.

Corradini, I., Donzelli, A., Antonucci, F., Welzl, H., Loos, M., Martucci, R., Astis, S. D., Pattini, L., Inverardi, F., Wolfer, D., et al. (2014) · Cerebral Cortex · doi:10.1093/cercor/bhs316 · Cited by 91 · see citing works

Pharmacotherapy for mental health problems in people with intellectual disability

Ji, N. Y., & Findling, R. L. (2016) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000233 · Cited by 77 · see citing works

Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development

Nierenberg, A. A., Kansky, C., Brennan, B. P., Shelton, R. C., Perlis, R. H., & Iosifescu, D. V. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412449303 · Cited by 76 · see citing works

Epigenetics of fragile X syndrome and fragile X‐related disorders

Kraan, C. M., Godler, D. E., & Amor, D. J. (2018) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.13985 · Cited by 74 · see citing works

Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys

Torrioli, M., Vernacotola, S., Setini, C., Bevilacqua, F., Martinelli, D., Snape, M., Hutchison, J. A., Di Raimo, F. R., Tabolacci, E., & Neri, G. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33484 · Cited by 71 · see citing works

Fragile X mental retardation protein has a unique, evolutionarily conserved neuronal function not shared with FXR1P or FXR2P

Coffee, R. L., Tessier, C. R., Woodruff, E. A., & Broadie, K. S. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.004598 · Cited by 71 · see citing works

Biomarker-guided interventions of clinically relevant conditions associated with autism spectrum disorders and attention deficit hyperactivity disorder.

Bradstreet, J. J., Smith, S. A., Baral, M., & Rossignol, D. A. (2010) · PubMed · Cited by 71 · see citing works

Public Health Literature Review of Fragile X Syndrome

Raspa, M., Wheeler, A., & Riley, C. M. (2017) · PEDIATRICS · doi:10.1542/peds.2016-1159c · Cited by 61 · see citing works

Treatments for fragile X syndrome: A closer look at the data

Hall, S. S. (2009) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.78 · Cited by 56 · see citing works

Potential Role of L-Carnitine in Autism Spectrum Disorder

Kępka, A., Ochocińska, A., Chojnowska, S., Borzym‐Κluczyk, M., Skorupa, E., Knaś, M., & Waszkiewicz, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061202 · Cited by 53 · see citing works

DNA Methylation, Mechanisms of FMR1 Inactivation and Therapeutic Perspectives for Fragile X Syndrome

Nobile, V., Pucci, C., Chiurazzi, P., Neri, G., & Tabolacci, E. (2021) · Biomolecules · doi:10.3390/biom11020296 · Cited by 50 · see citing works

The FRAXopathies: Definition, overview, and update

Pirozzi, F., Tabolacci, E., & Neri, G. (2011) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.34113 · Cited by 46 · see citing works

The fragile X mental retardation protein developmentally regulates the strength and fidelity of calcium signaling in Drosophila mushroom body neurons

Tessier, C. R., & Broadie, K. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.09.002 · Cited by 44 · see citing works

Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis

Curie, A., Yang, K., Kirsch, I., Gollub, R. L., des Portes, V., Kaptchuk, T. J., & Jensen, K. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133316 · Cited by 43 · see citing works

Emerging pharmacologic treatment options for fragile X syndrome

Erickson, C. A., Schaefer, T. L., & Davenport, M. H. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s35673 · Cited by 43 · see citing works

Review of pharmacotherapy options for the treatment of attention‐deficit/hyperactivity disorder (ADHD) and ADHD‐like symptoms in children and adolescents with developmental disorders

Rowles, B. M., & Findling, R. L. (2010) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.120 · Cited by 40 · see citing works

Systematic review of pharmacological treatments in fragile X syndrome

Rueda, J.-R., Ballesteros, J., & Tejada, M. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-53 · Cited by 39 · see citing works

The Fragile X Mental Retardation Protein in Circadian Rhythmicity and Memory Consolidation

Gatto, C. L., & Broadie, K. S. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8057-0 · Cited by 38 · see citing works

A Comparative Perspective on Wnt/β-Catenin Signalling in Cell Fate Determination

Garcin, C. L., & Habib, S. J. (2017) · Results and problems in cell differentiation · doi:10.1007/978-3-319-53150-2_15 · Cited by 36 · see citing works

Transcriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X Syndrome

Tabolacci, E., Palumbo, F., Nobile, V., & Neri, G. (2016) · Genes · doi:10.3390/genes7080049 · Cited by 37 · see citing works

Epigenetics, fragile X syndrome and transcriptional therapy

Tabolacci, E., & Chiurazzi, P. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36264 · Cited by 35 · see citing works

Acetyl-L-Carnitine as an Adjunctive Therapy in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Placebo-Controlled Trial

Abbasi, S.-H., Heidari, S., Mohammadi, M.-R., Tabrizi, M., Ghaleiha, A., & Akhondzadeh, S. (2011) · Child Psychiatry & Human Development · doi:10.1007/s10578-011-0220-y · Cited by 34 · see citing works

Genome-wide methylation analysis demonstrates that 5-aza-2-deoxycytidine treatment does not cause random DNA demethylation in fragile X syndrome cells

Tabolacci, E., Mancano, G., Lanni, S., Palumbo, F., Goracci, M., Ferrè, F., Helmer‐Citterich, M., & Neri, G. (2016) · Epigenetics & Chromatin · doi:10.1186/s13072-016-0060-x · Cited by 33 · see citing works

Natural Product-Derived Treatments for Attention-Deficit/Hyperactivity Disorder: Safety, Efficacy, and Therapeutic Potential of Combination Therapy

Ahn, J. C., Ahn, H. S., Cheong, J. H., & Peña, I. D. (2016) · Neural Plasticity · doi:10.1155/2016/1320423 · Cited by 33 · see citing works

Fragile X Syndrome: Psychiatric Manifestations, Assessment and Emerging Therapies

Wadell, P. M., Hagerman, R. J., & Hessl, D. R. (2013) · Current Psychiatry Reviews · doi:10.2174/157340013805289644 · Cited by 32 · see citing works

Effects of l-Carnitine in Patients with Autism Spectrum Disorders: Review of Clinical Studies

Malaguarnera, M., & Cauli, O. (2019) · Molecules · doi:10.3390/molecules24234262 · Cited by 30 · see citing works

Modelling fragile X syndrome in the laboratory setting: A behavioral perspective

Melancia, F., & Trezza, V. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.04.042 · Cited by 29 · see citing works

Current Experience in Testing Mitochondrial Nutrients in Disorders Featuring Oxidative Stress and Mitochondrial Dysfunction: Rational Design of Chemoprevention Trials

Pagano, G., Talamanca, A. A., Castello, G., Cordero, M. D., d’Ischia, M., Gadaleta, M. N., Pallardó, F. V., Petrović, S. Ž., Tiano, L., & Zatterale, A. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151120169 · Cited by 27 · see citing works

Treatment effects of stimulant medication in young boys with fragile X syndrome

Roberts, J. E., Miranda, M., Boccia, M. L., Janes, H., Tonnsen, B. L., & Hatton, D. D. (2011) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-011-9085-4 · Cited by 25 · see citing works

Acetyl-l-carnitine versus placebo for migraine prophylaxis: A randomized, triple-blind, crossover study

Hagen, K., Brenner, E., Linde, M., Gravdahl, G. B., Tronvik, E., Engstrøm, M., Sonnewald, U., Helde, G., Stovner, L. J., & Sand, T. (2015) · Cephalalgia · doi:10.1177/0333102414566817 · Cited by 23 · see citing works

ADHD and nutritional supplements

Glanzman, M. M. (2009) · Current Attention Disorders Reports · doi:10.1007/s12618-009-0011-6 · Cited by 17 · see citing works

Effects of clonidine and methylphenidate on motor activity in Fmr1 knockout mice

Wrenn, C. C., Heitzer, A. M., Roth, A. K., Nawrocki, L., & Valdovinos, M. G. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.11.035 · Cited by 17 · see citing works

Annual Research Review: Rare genotypes and childhood psychopathology – uncovering diverse developmental mechanisms of ADHD risk

Scerif, G., & Baker, K. (2014) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12374 · Cited by 17 · see citing works

Working Memory Training in Youth With Autism, Fragile X, and Intellectual Disability: A Pilot Study

Calub, C. A., Benyakorn, S., Sun, S., Iosif, A., Boyle, L. H., Solomon, M., Hessl, D. R., & Schweitzer, J. B. (2022) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-127.5.369 · Cited by 15 · see citing works

Phenotypic variability to medication management: an update on fragile X syndrome

Elhawary, N. A., AlJahdali, I. A., Abumansour, I. S., Azher, Z. A., Falemban, A. H., Madani, W. M., Alosaimi, W., Alghamdi, G., & Sindi, I. A. (2023) · Human Genomics · doi:10.1186/s40246-023-00507-2 · Cited by 14 · see citing works

Fragile X syndrome in children

Acero-Garcés, D. O., Saldarriaga, W., Cabal-Herrera, A. M., Cerón, C. A. R., & Hagerman, R. J. (2023) · Colombia medica · doi:10.25100/cm.v54i2.5089 · Cited by 14 · see citing works

Fragile X Syndrome: A Psychiatric Perspective

Tranfaglia, M. R. (2011) · Results and problems in cell differentiation · doi:10.1007/978-3-642-21649-7_16 · Cited by 14 · see citing works

A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial

de Diego‐Otero, Y., Medina, R. C., Quintero-Navarro, C., Salido, L. S., García-Guirado, F., del Arco, I., Fernández-Carvajal, I., Ferrando-Lucas, T., Caballero‐Andaluz, R., & Pérez-Costillas, L. (2014) · Trials · doi:10.1186/1745-6215-15-345 · Cited by 13 · see citing works

Autism Spectrum Disorders

Freitag, C. M., & Jarczok, T. A. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1501-5_13 · Cited by 13 · see citing works

Carnitine Responsive Migraine Headache Syndrome: Case Report and Review of the Literature

Charleston, L. I., Khalil, S., & Young, W. B. (2021) · Current Pain and Headache Reports · doi:10.1007/s11916-021-00936-5 · Cited by 11 · see citing works

Mitochondrial dysfunction in Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome: prospect use of antioxidants and mitochondrial nutrients

Pagano, G., Lyakhovich, A., Pallardó, F. V., Tiano, L., Zatterale, A., & Trifuoggi, M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09415-7 · Cited by 10 · see citing works

Aspectos clínicos, moleculares y farmacológicos en los trastornos asociados a gen 1 del retraso mental del X frágil

Pugin, A., Faùndes, V., María, L. S., Curotto, B., Aliaga, S., Salas, I., Soto, P., Bravo, P. E., Pena, M., & Alliende, M. A. (2014) · Neurología · doi:10.1016/j.nrl.2014.10.009 · Cited by 9 · see citing works

Methyl‐CpG‐Binding PCR of Bloodspots for Confirmation of Fragile X Syndrome in Males

Tzeng, C., Liou, C., Li, C., Lai, M., Tsai, L., Cho, W.-C., & Chang, H.-T. (2009) · BioMed Research International · doi:10.1155/2009/643692 · Cited by 7 · see citing works

Molecular medicine of fragile X syndrome: based on known molecular mechanisms

Luo, S.-Y., Wu, L., & Duan, R. (2015) · World Journal of Pediatrics · doi:10.1007/s12519-015-0052-0 · Cited by 6 · see citing works

Drug policy and treatment bias due to the dopamine-deficit theory of child attention-deficit hyperactivity disorder

Rastmanesh, R. (2010) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-010-0033-z · Cited by 6 · see citing works

Autismus-Spektrum-Störungen

Freitag, C. M., & Jarczok, T. A. (2016) · Springer eBooks · doi:10.1007/978-3-662-48624-5_13 · Cited by 6 · see citing works

Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence

Watkins, L. V., Moon, S., Burrows, L., Tromans, S. J., Barwell, J., & Shankar, R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2323605 · Cited by 5 · see citing works

L-acetylcarnitine for treating fragile X syndrome

Rueda, J.-R., Guillén, V., Ballesteros, J., Tejada, M., & Solà, I. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010012.pub2 · Cited by 6 · see citing works

Clinical, molecular, and pharmacological aspects of FMR1 -related disorders

Pugin, A., Faùndes, V., María, L. S., Curotto, B., Aliaga, S., Salas, I., Soto, P., Bravo, P. E., Pena, M., & Alliende, M. A. (2016) · Neurología (English Edition) · doi:10.1016/j.nrleng.2014.10.018 · Cited by 4 · see citing works

Disorders of elastic tissue

Weedon, D. D. (2010) · Elsevier eBooks · doi:10.1016/b978-0-7020-3485-5.00013-9 · Cited by 4 · see citing works

Fragile X syndrome and associated disorders

Cornish, K. M., Gray, K. M., & Rinehart, N. (2010) · Advances in child development and behavior · doi:10.1016/b978-0-12-374748-8.00006-8 · Cited by 4 · see citing works

Psychopharmacology of neurobehavioral disorders

Mooney, L. N., Dominick, K. C., & Erickson, C. A. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00023-x · Cited by 3 · see citing works

Integrative and Complementary Medicine in Psychiatry

Sarris, J. J., Gerbarg, P. L., Brown, R. P., & Muskin, P. R. (2015) · doi:10.1002/9781118753378.ch110 · Cited by 3 · see citing works

Clinical Practice Guideline for Patients with Attention Deficit/Hyperactivity Disorder

Carlton, T. G., Donachie, N., Frampton, K. K., Henschen, G., Kumar, P. E., Parrot, L. A., Smith, C. A., Tamil, F. A., Valenti, A. M., & Waxenberg, F. (2014) · Cited by 2 · see citing works

Reflections on Clinical Trials in Fragile X Syndrome

Jønch, A. E., & Jacquemont, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00020-2 · Cited by 2 · see citing works

Integrative Management of ADHD: What the Evidence Suggests

Lake, J. (2010) · Cited by 2 · see citing works

Medication Management of Fragile X Syndrome

Erickson, C. A., Wink, L. K., Schaefer, T. L., & Shaffer, R. C. (2013) · Springer eBooks · doi:10.1007/978-1-4614-4788-7_188 · Cited by 2 · see citing works

Phase II and III drugs for the treatment of fragile X syndrome

Politte, L. C., & McDougle, C. J. (2012) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2013.750240 · Cited by 1 · see citing works

Epigenetic causes of intellectual disability—the fragile X syndrome paradigm

Tabolacci, E., & Neri, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800226-1.00006-x · Cited by 1 · see citing works

Integrative and Complementary Medicine in Psychiatry

Sarris, J. J., Gerbarg, P. L., Brown, R. P., & Muskin, P. R. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_145-1 · Cited by 1 · see citing works

Epigenetic causes of intellectual disability—the fragile X syndrome paradigm

Tabolacci, E., & Neri, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18516-8.00007-7 · Cited by 1 · see citing works

Integrative and Complementary Medicine in Psychiatry

Sarris, J. J., Gerbarg, P. L., Brown, R. P., & Muskin, P. R. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_145 · Cited by 1 · see citing works

Transcription and protein synthesis inhibitors influence long-term effects of acetyl-l-carnitine on non-associative learning in the leech

Traina, G., & Scuri, R. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.11.007 · Cited by 1 · see citing works

The role of acetyl-L-carnitine (LAC) in the treatment of mental disorders

Stelmach, E., Romanowski, M., & Olajossy, M. (2019) · Current Problems of Psychiatry · doi:10.2478/cpp-2019-0017 · Cited by 1 · see citing works

Insights into the human Fragile X syndrome gene family using Drosophila melanogaster

Coffee, R. L. (2011) · Cited by 1 · see citing works

Interventions

Hemmings, C. P., & Bouras, N. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781107588714.014 · Cited by 1 · see citing works

The role of nutrition and diet in learning and behaviour of children with symptoms of attention deficit hyperactivity disorder

Sinn, N., & Rucklidge, J. J. (2011) · Elsevier eBooks · doi:10.1533/9780857092922.3.323

Oral Ascorbic Acid and Alpha-Tocopherol to Reduce Behavioural Problems in Young Patients Affected of Fragile X Syndrome: A Randomized, Double-Blind, Placebo-Controlled Phase II Pilot Trial

de Diego‐Otero, Y., Quintero-Navarro, C., Medina, R. C., Heredia‐Farfan, R., Salido, L. S., Lima‐Cabello, E., Higuero-Tapiador, A., Del, I., Fernández-Carvajal, I., Ferrando-Lucas, T., et al. (2012) · InTech eBooks · doi:10.5772/29480

Updates on the Use of Natural Treatments for Attention-Deficit Hyperactivity Disorder (ADHD)

de la Peña, J. B., Botanas, C. J., Tampus, R., Peña, I. J. D., Kim, H. J., Peña, I. D., & Cheong, J. H. (2015) · InTech eBooks · doi:10.5772/60840

DIAGNOSIS AUTISM: NOW WHAT? A SIMPLIFIED BIOMEDICAL

Rossignol, D. (2009)

CAUSES AND CONSEQUENCES OF REDUCED EXPRESSION OF SNAP-25 IN NEURONAL NETWORKS

Astis, S. D. (2012) · Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) · doi:10.13130/de-astis-silvia_phd2013-01-16

12 Disorders of elastic tissue

BUNTING, J. J. (2010) · Elsevier eBooks · doi:10.1016/b978-0-7020-3485-5.00054-1

What Mechanisms Induce Methylation of FMR1 Gene Full Mutation? A Still Unanswered Question

Tabolacci, E., & Neri, G. (2016) · Epigenetics and human health · doi:10.1007/978-3-319-27186-6_8

Reactivation of the FMR1 Gene

Tabolacci, E., & Chiurazzi, P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00017-2

Carnitine

Sadlon, A. E., & Murray, M. T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-43044-9.00063-7

References

(2010) · Wiley eBooks · doi:10.1002/9781118269954.refs

Influence of Amino Acids on Autism and Attention-Deficit Hyperactive Disorder

Begum, P. S., Razak, M. A., & Rajagopal, S. (2022) · Nutritional neurosciences · doi:10.1007/978-981-15-9781-7_10

Therapeutic Approaches for Attention Deficit-Hyperactivity Disorder

Justin‐Thenmozhi, A., Manivasagam, T., & Borah, A. (2022) · Nutritional neurosciences · doi:10.1007/978-981-15-9781-7_9

Carnitine

Sadlon, A. E., & Murray, M. T. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-2333-5.00074-2

La Vineland-II dans la recherche interventionnelle sur l’autisme : une revue de la littérature

Zaghzi, C., Moine, V., Albuisson, É., & Kabuth, B. (2022) · Neuropsychiatrie de l Enfance et de l Adolescence · doi:10.1016/j.neurenf.2022.09.003

Measuring Effectiveness of Treatments in Rare Disorders, Evidence from Clinical Trials in Fragile X SyndromePreprint

Steenbergen, A. V., Minhas, A., Lin, T. R., Kaur, M., & Bolduc, F. V. (2023) · Research Square · doi:10.21203/rs.3.rs-3439158/v1

Characterization of in vitro models for evaluation of molecular mechanisms involved in the action of Acetyl-L-Carnitine

Lapa, J. F. R. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)

[L-acetylcarnitine treatment on fragile X patients hyperactive behaviour].

Calvani, M., D'Iddio, S., Gaetano, A. D., Mariotti, P., Mosconi, L., Pomponi, M. G., Tabolacci, E., Torrioli, M. G., Vernacotola, S., & Neri, G. (2001) · PubMed · Cited by 4 · see citing works

L-acetylcarnitine for treating fragile X syndrome

Rueda, J.-R., Guillén, V., Ballesteros, J., Tejada, M., & Solà, I. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010012.pub2 · Cited by 6 · see citing works

Autosomal XX sex reversal caused by duplication ofSOX9

Huang, B., Wang, S., Ning, Y., Lamb, A. N., & Bartley, J. A. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19991203)87:4 · Cited by 424 · see citing works

Acetyl-L-Carnitine as an Adjunctive Therapy in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Placebo-Controlled Trial

Abbasi, S.-H., Heidari, S., Mohammadi, M.-R., Tabrizi, M., Ghaleiha, A., & Akhondzadeh, S. (2011) · Child Psychiatry & Human Development · doi:10.1007/s10578-011-0220-y · Cited by 34 · see citing works

Is Acetyl-L-Carnitine Effective and Safe in Treating Children with ADHD?

Dominique, K. (2019) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)